Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

8.0K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.0K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

3.4K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

5.3K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.3K
Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists01:27

Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists

391
5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...
391
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

5.1K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
5.1K
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists01:28

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

302
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy.  SP binds and activates...
302

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Response to mirvetuximab soravtansine and weekly paclitaxel based on treatment sequencing in platinum-resistant ovarian cancer: Does order matter?

Gynecologic oncology·2026
Same author

Multifunctional Self-Bonding Biocomposites Enabled by Uniform Dispersion of Carbon Nanotube via In Situ Lignin and Multiple Noncovalent Bonds.

Small (Weinheim an der Bergstrasse, Germany)·2026
Same author

PRO-PLATINUM: A randomized, double-blind, placebo controlled study to investigate the efficacy of a probiotic intervention on the gut and vaginal microbiome of ovarian cancer patients undergoing treatment with platinum chemotherapy.

Gynecologic oncology·2026
Same author

Soil eDNA Biomonitoring: Assessing Efficacy for Detecting Terrestrial Vertebrate and Plant Biodiversity.

Environmental science & technology·2026
Same author

Association between alcohol consumption and Internet addiction in teenagers: A cross-sectional study in China.

Acta psychologica·2026
Same author

Retinoic acid-driven expansion of CD16hiCD177+ neutrophils mediates steroid-resistant GI-GVHD.

Blood·2026

Related Experiment Video

Updated: Oct 20, 2025

Visualizing DNA Damage Repair Proteins in Patient-Derived Ovarian Cancer Organoids via Immunofluorescence Assays
04:07

Visualizing DNA Damage Repair Proteins in Patient-Derived Ovarian Cancer Organoids via Immunofluorescence Assays

Published on: February 24, 2023

1.9K

PARP inhibitors decrease response to subsequent platinum-based chemotherapy in patients with BRCA mutated ovarian

Peter G Rose1,2, Meng Yao3, Laura M Chambers1,2

  • 1Section of Gynecologic Oncology.

Anti-Cancer Drugs
|September 14, 2021
PubMed
Summary
This summary is machine-generated.

Prior use of poly-adenosine ribose phosphatase inhibitors (PARPi) significantly reduced progression-free survival (PFS) in patients with recurrent BRCA-mutated ovarian cancer receiving subsequent platinum-based chemotherapy (PBC). PARPi exposure negated the benefits of platinum retreatment.

More Related Videos

Silencing of BRCA2 to Identify Novel BRCA2-regulated Biological Functions in Cultured Human Cells
09:24

Silencing of BRCA2 to Identify Novel BRCA2-regulated Biological Functions in Cultured Human Cells

Published on: August 12, 2015

9.3K
Evaluating the Effectiveness of Cancer Drug Sensitization In Vitro and In Vivo
09:19

Evaluating the Effectiveness of Cancer Drug Sensitization In Vitro and In Vivo

Published on: February 6, 2015

8.8K

Related Experiment Videos

Last Updated: Oct 20, 2025

Visualizing DNA Damage Repair Proteins in Patient-Derived Ovarian Cancer Organoids via Immunofluorescence Assays
04:07

Visualizing DNA Damage Repair Proteins in Patient-Derived Ovarian Cancer Organoids via Immunofluorescence Assays

Published on: February 24, 2023

1.9K
Silencing of BRCA2 to Identify Novel BRCA2-regulated Biological Functions in Cultured Human Cells
09:24

Silencing of BRCA2 to Identify Novel BRCA2-regulated Biological Functions in Cultured Human Cells

Published on: August 12, 2015

9.3K
Evaluating the Effectiveness of Cancer Drug Sensitization In Vitro and In Vivo
09:19

Evaluating the Effectiveness of Cancer Drug Sensitization In Vitro and In Vivo

Published on: February 6, 2015

8.8K

Area of Science:

  • Oncology
  • Genetics
  • Pharmacology

Background:

  • Recurrent ovarian cancer treatment often involves platinum-based chemotherapy (PBC).
  • Poly-adenosine ribose phosphatase inhibitors (PARPi) are used in BRCA-mutated cancers.
  • The impact of prior PARPi use on subsequent PBC response in BRCA-mutated epithelial ovarian cancer (BRCAm EOC) is not fully understood.

Purpose of the Study:

  • To evaluate the effect of prior PARPi treatment on the efficacy of subsequent PBC in patients with recurrent, platinum-sensitive BRCAm EOC.
  • To compare progression-free survival (PFS) to subsequent PBC in BRCAm EOC patients with and without prior PARPi exposure.
  • To assess if PARPi exposure alters the prognostic significance of platinum-free intervals and BRCA mutational status.

Main Methods:

  • Retrospective, single-institution cohort study.
  • Analysis of 115 patients receiving 2nd PBC and 55 receiving 3rd PBC for recurrent BRCAm EOC.
  • Comparison of PFS to subsequent PBC between patients with and without prior PARPi exposure, including BRCAm and non-BRCAm groups.

Main Results:

  • Patients without prior PARPi had significantly longer PFS to 2nd (2.3x) and 3rd (2.4x) PBC.
  • Among 20 PARPi-exposed BRCAm EOC patients, PFS to 2nd/3rd PBC was significantly worse (8.0 months vs. 19.1 months, HR 4.01).
  • PARPi exposure diminished the prognostic value of platinum-free intervals and BRCA mutational status.

Conclusions:

  • Prior PARPi exposure significantly reduces the effectiveness of subsequent platinum-based chemotherapy in recurrent BRCAm EOC.
  • PARPi treatment appears to abrogate the established prognostic factors in platinum-sensitive recurrent ovarian cancer.
  • These findings suggest a need to reconsider treatment sequencing in BRCAm EOC patients.